PA
TRDA icon

Parallel Advisors’s Entrada Therapeutics TRDA Stock Holding History

Parallel Advisors’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-16
Closed -$277 – 3668
2024
Q4 		$277 Buy
+16
New +$290 ﹤0.01% 3330

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Parallel Advisors's TRDA Position: Q1 2025 in Review

Parallel Advisors sold out of Entrada Therapeutics (TRDA) in Q1 2025, closing a stake of 16 shares — an estimated $277 sold.

Parallel Advisors first reported a position in TRDA in Q4 2024 and held it in 1 quarter. The position peaked at $277 in Q4 2024. 111 funds tracked by Wall St. Rank hold TRDA as of Q1 2025.

  • Parallel Advisors reported no remaining Entrada Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Parallel Advisors sold 16 Entrada Therapeutics shares in Q1 2025, an estimated $277.
  • Parallel Advisors first reported a position in Entrada Therapeutics in Q4 2024 and held it in 1 quarter.
  • Parallel Advisors's Entrada Therapeutics position peaked at $277 in Q4 2024.
  • 111 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2025.

Based on Parallel Advisors's 13F filing for Q1 2025, filed 8 Apr 2025.